MMP9 and breast carcinoma: At a concentration of 4 mg/mL (PLE PI), 2 mg/mL (HIFU PI), and 2.4 mg/mL (hydrolysates), all treatments significantly reduced breast cancer cell migration and metalloproteinase 9 (MMP-9) activity (active and pro form), and enhanced cell adhesion.